Skip to content
Advertisement

FILE - This handout  file photo taken Sept. 2, 2014, provided by National Institute of Allergy and Infectious Diseases (NIAID) shows A 39-year-old woman, the first participant enrolled in VRC 207, receiving a dose of the investigational NIAID/GSK Ebola vaccine at the NIH Clinical Center in Bethesda, Md. As West Africa struggles to contain the biggest ever outbreak of Ebola, some experts say an unusual but simple treatment might help: the blood of survivors.  The evidence is mixed for using infection-fighting antibodies from survivors’ blood for Ebola, but without any licensed drugs or vaccines for the deadly disease, some say it’s worth a shot.  (AP Photo/NIAID, File)

FILE - This handout file photo taken Sept. 2, 2014, provided by National Institute of Allergy and Infectious Diseases (NIAID) shows A 39-year-old woman, the first participant enrolled in VRC 207, receiving a dose of the investigational NIAID/GSK Ebola vaccine at the NIH Clinical Center in Bethesda, Md. As West Africa struggles to contain the biggest ever outbreak of Ebola, some experts say an unusual but simple treatment might help: the blood of survivors. The evidence is mixed for using infection-fighting antibodies from survivors’ blood for Ebola, but without any licensed drugs or vaccines for the deadly disease, some say it’s worth a shot. (AP Photo/NIAID, File)

Featured Photo Galleries